Clinical evaluation company The IMA Group (IMA) revealed on Tuesday the completion of the acquisition of Diagnostics Research Group (DXRG) in San Antonio, Texas for an undisclosed amount.
Diagnostics Research Group (DXRG) reportedly provides expertise across a diverse array of medical specialties, including vaccine and medical device development, internal medicine, allergies and pulmonary and fatty liver diseases.
Following closing, DXRG will continue to operate under its current name, with key leadership, investigators and staff remaining in place.
The acquisition which marks IMA's fourth this year adds to its growing Clinical Research Division and aligns with its mission to reach people everywhere as it partners with its sponsors to develop safe and effective new treatments. In addition it extends its access to diverse patient populations and its expansion into the southwestern US.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval